OBJECTIVE: To evaluate the prevalence and significance of focal thyroid lesions identified by (18)F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients with nonthyroidal head and neck cancers (HNC). PATIENTS AND MEASUREMENTS: Patients with histologically identified HNC who underwent FDG-PET and computed tomography (CT) were reviewed retrospectively. We evaluated the prevalence of patients with focal thyroid FDG uptake and the risk of malignancy and proper management in these patients. RESULTS: Of 689 HNC patients, 19 (2.8%) had focal thyroid FDG uptake. Of the 12 patients with a histological diagnosis by surgery or needle biopsy, 5 (41.7%) had carcinomas, 4 papillary and 1 follicular, whereas the others had benign thyroid lesions. The maximum standardized uptake value on PET was not sufficient to discriminate between malignant and benign thyroid lesions (8.4 +/- 13.2 vs. 4.2 +/- 4.0; P > 0.4). The identification of incidental thyroid diseases helped guide patient counselling and combined surgery with HNC and thyroidectomy. CONCLUSION: Focal thyroid lesions incidentally found on FDG-PET in patents with nonthyroidal HNC have a high probability of malignancy. These lesions deserve further diagnostic examination before HNC treatment to ensure adequate therapy for incidental thyroid cancers.
OBJECTIVE: To evaluate the prevalence and significance of focal thyroid lesions identified by (18)F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients with nonthyroidal head and neck cancers (HNC). PATIENTS AND MEASUREMENTS: Patients with histologically identified HNC who underwent FDG-PET and computed tomography (CT) were reviewed retrospectively. We evaluated the prevalence of patients with focal thyroid FDG uptake and the risk of malignancy and proper management in these patients. RESULTS: Of 689 HNC patients, 19 (2.8%) had focal thyroid FDG uptake. Of the 12 patients with a histological diagnosis by surgery or needle biopsy, 5 (41.7%) had carcinomas, 4 papillary and 1 follicular, whereas the others had benign thyroid lesions. The maximum standardized uptake value on PET was not sufficient to discriminate between malignant and benign thyroid lesions (8.4 +/- 13.2 vs. 4.2 +/- 4.0; P > 0.4). The identification of incidental thyroid diseases helped guide patient counselling and combined surgery with HNC and thyroidectomy. CONCLUSION: Focal thyroid lesions incidentally found on FDG-PET in patents with nonthyroidal HNC have a high probability of malignancy. These lesions deserve further diagnostic examination before HNC treatment to ensure adequate therapy for incidental thyroid cancers.
Authors: Sharouz Bonabi; Felix Schmidt; Martina A Broglie; Sarah R Haile; Sandro J Stoeckli Journal: Eur Arch Otorhinolaryngol Date: 2012-12 Impact factor: 2.503
Authors: N G Iyer; Ashok R Shaha; Carl E Silver; Kenneth O Devaney; Alessandra Rinaldo; Phillip K Pellitteri; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2010-02-13 Impact factor: 2.503
Authors: A Reum Chun; Hye Min Jo; Seoung Ho Lee; Hong Woo Chun; Jung Mi Park; Kyu Jin Kim; Chan Hee Jung; Ji Oh Mok; Sung Koo Kang; Chul Hee Kim; Bo Yeon Kim Journal: Endocrinol Metab (Seoul) Date: 2014-07-18
Authors: M M Yalcin; A E Altinova; C Ozkan; F Toruner; M Akturk; O Akdemir; T Emiroglu; D Gokce; A Poyraz; F Taneri; I Yetkin Journal: Acta Endocrinol (Buchar) Date: 2016 Apr-Jun Impact factor: 0.877